Logo image
Revisiting "older" antimicrobials in the era of multidrug resistance
Journal article   Peer reviewed

Revisiting "older" antimicrobials in the era of multidrug resistance

Jason M Pogue, Dror Marchaim, Donald Kaye and Keith S Kaye
Pharmacotherapy, v 31(9), pp 912-921
Sep 2011
PMID: 21923592

Abstract

Anti-Infective Agents - economics Anti-Infective Agents - pharmacology Anti-Infective Agents - therapeutic use Drug Costs Drug Resistance, Multiple, Bacterial - drug effects Humans
Infections due to multidrug-resistant (MDR) organisms continue to increase, and the antimicrobial pipeline remains unacceptably lean. Given this challenge, it is has become necessary to use older antimicrobials for treatment of MDR pathogens despite concerns regarding toxicity and the lack of clinical efficacy data. In some cases, older antimicrobials offer potential advantages compared with new agents, including lower cost and better in vitro activity. In this review, we focus on the pharmacology, in vitro activity, and clinical experience of older agents, including colistin, minocycline, trimethoprim-sulfamethoxazole, and fosfomycin. We also discuss some new antimicrobial agents that are used to treat MDR pathogens. As MDR pathogens continue to outpace the development of new antimicrobials, it will become imperative to develop strategies regarding the optimal use of older agents in terms of monotherapy versus combination therapy, dosing regimens, and treatment of invasive infections caused by these pathogens.

Metrics

10 Record Views
45 citations in Scopus

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Collaboration types
Domestic collaboration
Web of Science research areas
Pharmacology & Pharmacy
Logo image